Niihara Yutaka's Form 4 filing
Emmaus Life Sciences, Inc. (EMMA) · filed Feb 11, 2022
- Accession no.
- 0001209191-22-008917
- Filed
- Feb 11, 2022
- Trade date
- Feb 9-11, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market purchases total $44.4K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Niihara YutakaCIK 0001517691 | Director, Officer (Chairman and CEO), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 9, 2022 | Common stock, $0.001 par value | PPurchaseAcquired | +23,500 | $1.45 | +$34,075 | 11,187,406 | Direct | |
| Feb 10, 2022 | Common stock, $0.001 par value | PPurchaseAcquired | +3,000 | $1.45 | +$4,350 | 11,190,406 | Direct | |
| Feb 11, 2022 | Common stock, $0.001 par value | PPurchaseAcquired | +4,000 | $1.49 | +$5,960 | 11,194,406 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.